<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901588</url>
  </required_header>
  <id_info>
    <org_study_id>S12-00556</org_study_id>
    <nct_id>NCT01901588</nct_id>
  </id_info>
  <brief_title>Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery</brief_title>
  <official_title>Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is trying to see if using precedex pre-operatively prevents emergence delirium in
      pediatric (ages 1-7) patients undergoing strabismus surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emergence delirium (ED) is a complex behavioral disturbance characterized by psychomotor
      agitation, perceptual disturbances, delusions, and disorientation during recovery from
      general anesthesia. In the population of subjects who undergo strabismus surgery, there are
      multiple factors that may increase the risk of ED. These include age, typically preschool
      children aged 1-7 years, rapid surgical times with rapid awakening, use of sevoflurane as the
      primary anesthetic, and surgically-induced postoperative visual disturbance. The aims of this
      study are: 1) To examine whether post-induction treatment with an Î±-2 receptor agonist,
      precedex (dexmedetomidine), decreases postoperative emergence agitation after strabismus
      surgery compared to placebo, and 2) to determine whether treatment has any effect on
      postoperative pain, nausea/vomiting, number of pain-related interventions, and time to PACU
      discharge. We hypothesize that precedex will attenuate the ED response greater than placebo
      or a lower dose after strabismus surgery and will reduce PACU pain scores without increasing
      PACU length of stay.

      Inclusion:

      i. Pediatric patients aged 1-7 years of age ii. American Society of Anesthesiologists (ASA)
      physical status I-II iii. No significant laboratory abnormalities

      Exclusion:

      i. Presence of medicated behavioral disorder ii. Subjects for which precedex, opiates,
      benzodiazepines, or inhalational anesthetics are contraindicated iii. Parental refusal
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Experiencing Pediatric Emergence Delirium in Strabismus Surgery</measure>
    <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Receiving Pain Medication</measure>
    <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-op Pain Interventions</measure>
    <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Post-operative Nausea and Vomiting (PONV) Rescue Medications</measure>
    <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Arousal</measure>
    <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PACU Discharge</measure>
    <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Strabismus</condition>
  <condition>Delirium on Emergence</condition>
  <condition>Pediatric Disorders</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine/precedex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receive saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intraoperative dose of intravenous placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status of I or II

          -  male or female, aged 1-7

          -  has no significant lab abnormalities

        Exclusion Criteria:

          -  ASA physical status of III, IV or V

          -  Presence of medicated behavioral disorder

          -  Subjects for which dexmedetomidine, opiates, benzodiazepines or inhalational
             anesthetics are contraindicated.

          -  Parental refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <results_first_submitted>February 8, 2016</results_first_submitted>
  <results_first_submitted_qc>February 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2016</results_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>strabismus</keyword>
  <keyword>pediatric</keyword>
  <keyword>emergence delirium</keyword>
  <keyword>precedex/dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Emergence Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient's familes were approached on the day of surgery and spoken to privately in the pre-op area. Fliers were placed at the phthalmalogist's offices so were generally aware of the study ahead of time.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine</title>
          <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine</title>
          <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, Not of Hispanic-American Origin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White, not of Hispanic-American Origin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other or Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Experiencing Pediatric Emergence Delirium in Strabismus Surgery</title>
        <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing Pediatric Emergence Delirium in Strabismus Surgery</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Receiving Pain Medication</title>
        <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Pain Medication</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-op Pain Interventions</title>
        <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Post-op Pain Interventions</title>
          <units>number of pain interventions/group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Post-operative Nausea and Vomiting (PONV) Rescue Medications</title>
        <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Post-operative Nausea and Vomiting (PONV) Rescue Medications</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Arousal</title>
        <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Arousal</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="36"/>
                    <measurement group_id="O2" value="40" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PACU Discharge</title>
        <time_frame>Length of PACU stay (around 3 hours on average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PACU Discharge</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" spread="64"/>
                    <measurement group_id="O2" value="173" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine</title>
          <description>dexmedetomidine/precedex
Dexmedetomidine: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>patients receive saline solution.
Placebo: intraoperative dose of intravenous placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assistant Professor, Department of Anesthesiology, Perioperative Care, and Pain Medicine</name_or_title>
      <organization>NYU School of Medicine</organization>
      <phone>212.263.5072</phone>
      <email>wanda.chin@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

